Prestige Biopharma Limited

About Prestige Biopharma Limited

PRESTIGE BIOPHARMA LTD (PBP) is a rapidly-expanding, biopharmaceutical company, with an Innovative Drug Development Platform from Discovery to CMC analysis to GMP Product Manufacturing. We are pioneers in pancreatic cancer, with novel antibody drugs and diagnostics targeting PAUF (biomarker for pancreatic cancer) under development. We also specialize in development and manufacturing of biosimilars and vaccines.

  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Prestige Biopharma Limited (3)

  • PBP1510 (INN:ULENISTAMAB)

    Product PBP1510 (INN:ULENISTAMAB)

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells an...
  • PAUF Pancreatic Cancer Diagnostic Kit

    Product PAUF Pancreatic Cancer Diagnostic Kit

    Pancreatic Adenocarcinoma Up-regulated Factor- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC). With our expertise in biosimilars and novel antibody drugs development and manufacturing, we are strongly positioned to tackle the unaddressed need of pancreatic cancer. Early detection an...
  • PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Product PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinomaup-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer.

    It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer ce...

Prestige Biopharma Limited Resources (1)